Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area
复制标题
DOI：
10.1111/jgh.15468
复制
发表时间：
2021-03
影响因子：
4.1
通讯作者：
Chen Qiao;Yueyue Li;Jing Liu;C. Ji;Junyan Qu;Junnan Hu;Rui Ji;Meng Wan;Bo-Hoa Lin;M. Lin;Qingqing Qi;Xiu-li Zuo;Yanqing Li
中科院分区：
文献类型：
--
作者：
Chen Qiao;Yueyue Li;Jing Liu;C. Ji;Junyan Qu;Junnan Hu;Rui Ji;Meng Wan;Bo-Hoa Lin;M. Lin;Qingqing Qi;Xiu-li Zuo;Yanqing Li
抗生素耐药性的增加使根除幽门螺杆菌变得更加困难。考虑到药物敏感性引导疗法应用的局限性，寻找一种有效的经验性治疗方案非常重要。本研究的目的是比较以克拉霉素为基础的含铋四联疗法(C-BQT)和以呋喃唑酮为基础的含铋四联疗法(F-BQT)治疗幽门螺杆菌初治阳性患者的疗效、安全性和成本-效果。
The increase in antibiotic resistance makes the eradication of Helicobacter pylori more difficult. Considering the limitations of the application of susceptibility‐guided therapy, it is important to find an effective empirical regimen. The aim of the study is to compare the efficacy, safety, and cost‐effectiveness of clarithromycin‐based bismuth‐containing quadruple therapy (C‐BQT) and furazolidone‐based bismuth‐containing quadruple therapy (F‐BQT) in naïve H. pylori positive patients.